

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	To Be Assigned 10/589646
Filing Date	August 16, 2006
First Named Inventor	Jilly Evans
Group Art Unit	To Be Assigned 1614
Examiner Name	To Be Assigned TIM E. BETON
Attorney Docket Number	21238YP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			COMPLETE IF KNOWN		
			Application Number	To Be Assigned 9/589648	
			Filing Date	August 16, 2006	
			First Named Inventor	Jilly Evans	
			Group Art Unit	To Be Assigned 1614	
			Examiner Name	To Be Assigned TIM BETTON	
Sheet	2	of	3	Attorney Docket Number	21238YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
7EB	E	Database PUBMED on GOOGLE, Neurosurgical Clinic, Justus-Liebig University Giessen, (Germany), WINKING, M. et al., "Levels of Immunoreactive cysteinyl-leukotrienes in CSF after subarachnoid haemorrhage correlate with blood flow-velocity in TCD", abstract, Acta Neurochir (Wein), 139(8):764-769 (1997)
7EB	F	J. Takasaki et al., "The Molecular Characterization and Tissue Distribution.....," Biochemical and Biophysical Research Communications, Vol. 274, pp. 316-322 (2000)
7EB	G	M. Kamohara et al., "Functional Characterization of Cysteinyl Leukotriene.....," Biochemical and Biophysical Research Communications, Vol. 287, pp. 1088-1092 (2001)
7EB	H	J. Zhu et al., "Localization and Upregulation of Cysteinyl Leukotriene-1 Receptor in Asthmatic Bronchial Mucosa," Am J Respir Cell Mol Biol., Vol. 33, pp. 531-540 (2005)
7EB	I	G. Yang et al., "Transgenic smooth muscle expression of the human.....," Am J Physiol Lung Cell Mol Physiol., Vol. 286, pp. L992-1001 (2004)
7EB	J	K. Lotzer et al., "Differential Leukotriene Receptor Expression and Calcium Responses in Endothelial Cells and Macrophages Indicate.....," Arterioscler Thromb Basc Biol., Vol. 23, No. 8, pp. e32-6 (2003)
7EB	K	Galczenski et al., "Characterization of DUO-LT, a Novel Dual Cysteinyl Receptor Antagonist," presented at American Thoracic Society Meeting (April 2002)
7EB	L	H. Nothacker et al., "Molecular Cloning and Characterization of a Second Human Cysteinyl Leukotriene Receptor: Discovery of a Subtype Selective Agonist," Molecular Pharmacology, Vol. 58, No. 6, pp. 1601-1608 (2000)
7EB	M	C. Heise et al., "Characterization of the Human Cysteinyl Leukotriene 2 Receptor," J of Biological Chemistry, Vol. 275, No. 39, pp. 30531-30536 (2000)
7EB	N	H. Ogasawara et al., "Characterization of Mouse Cysteinyl Leukotriene Receptors mCysLT1 and mCysLT2", J of Biol Chem, Vol. 277, No. 21, pp. 18763-18768 (2002)
7EB	O	M. Golden et al., "Protection from Pulmonary Fibrosis in Leukotriene-Deficient Mice," Am J Respir Crit Care Med., Vol. 165, pp. 229-235 (2002)
7EB	P	J. Wilborn et al., "Constitutive Activation of 5-Lipoxygenase in the Lungs of Patients with Idiopathic Pulmonary Fibrosis," J. Clin. Invest., Vol. 97, No. 8, pp. 1827-1836 (1996)
7EB	Q	A. DiGennaro et al., "Cysteinyl-leukotriene receptor activation in brain inflammatory reactions and cerebral edema formation.....," The FASEB Journal express article 10.1096/fj.03-0599fje. Published online March 4, 2004.
7EB	R	A. DiGennaro et al., "Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral brain edema formation:.....," FASEB, Vol. 18, pp. 842-844 (May 2004)
7EB	S	L. Zhao et al., "The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm," Nature Medicine, Vol. 10, No. 9, pp. 966-973 (2004)

Examiner Signature		Date Considered	11/06/07
--------------------	---	-----------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2003